NASDAQ:GCTK GlucoTrack (GCTK) Stock Price, News & Analysis $0.36 +0.00 (+0.14%) Closing price 06/23/2026 04:00 PM EasternExtended Trading$0.36 0.00 (-0.93%) As of 06/23/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About GlucoTrack Stock (NASDAQ:GCTK) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get GlucoTrack alerts:Sign Up Key Stats Today's Range$0.35▼$0.3750-Day Range$0.36▼$0.9252-Week Range$0.29▼$15.90Volume216,812 shsAverage Volume1.01 million shsMarket Capitalization$2.28 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview GlucoTrack, Inc., a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey. Read More GlucoTrack Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks4th Percentile Overall ScoreGCTK MarketRank™: GlucoTrack scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingGlucoTrack has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageGlucoTrack has only been the subject of 1 research reports in the past 90 days.Read more about GlucoTrack's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of GlucoTrack is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GlucoTrack is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGlucoTrack has a P/B Ratio of 0.13. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.94% of the float of GlucoTrack has been sold short.Short Interest Ratio / Days to CoverGlucoTrack has a short interest ratio ("days to cover") of 0.48, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GlucoTrack has recently increased by 725.92%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGlucoTrack does not currently pay a dividend.Dividend GrowthGlucoTrack does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A MarketBeat Follows3 people have added GlucoTrack to their MarketBeat watchlist in the last 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, GlucoTrack insiders have not sold or bought any company stock.Percentage Held by Insiders2.23% of the stock of GlucoTrack is held by insiders.Percentage Held by Institutions10.92% of the stock of GlucoTrack is held by institutions.Read more about GlucoTrack's insider trading history. Receive GCTK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GlucoTrack and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GCTK Stock News HeadlinesGlucotrack to Highlight Implantable Continuous Blood Glucose Monitoring Technology at the American Diabetes Association’s 2026 Scientific SessionsMay 26, 2026 | markets.businessinsider.comGlucotrack to Highlight Implantable Continuous Blood Glucose Monitoring Technology at the American Diabetes Association's 2026 Scientific SessionsMay 26, 2026 | globenewswire.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result. | Porter & Company (Ad)GlucoTrack, Inc.: Glucotrack Reports First Quarter 2026 Financial Results and Recent Corporate HighlightsMay 15, 2026 | finanznachrichten.deGlucotrack Reports First Quarter 2026 Financial Results and Recent Corporate HighlightsMay 14, 2026 | globenewswire.comGlucoTrack Inc.May 13, 2026 | marketwatch.comRevolutionizing diabetes care: Discover the future of continuous glucose monitoringMay 11, 2026 | msn.comGlucotrack, Inc.: Glucotrack Announces IDE Submission for U.S. Clinical Study of its Novel Implantable Continuous Blood Glucose Monitoring TechnologyMay 8, 2026 | finanznachrichten.deSee More Headlines GCTK Stock Analysis - Frequently Asked Questions How have GCTK shares performed this year? GlucoTrack's stock was trading at $3.87 at the start of the year. Since then, GCTK shares have decreased by 90.6% and is now trading at $0.3644. How were GlucoTrack's earnings last quarter? GlucoTrack, Inc. (NASDAQ:GCTK) issued its earnings results on Thursday, August, 14th. The company reported ($9.62) EPS for the quarter. When did GlucoTrack's stock split? GlucoTrack shares reverse split before market open on Tuesday, February 4th 2025.The 1-20 reverse split was announced on Thursday, January 30th 2025. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 3rd 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of GlucoTrack? Shares of GCTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of GlucoTrack own? Based on aggregate information from My MarketBeat watchlists, some other companies that GlucoTrack investors own include Rolls-Royce Holdings PLC (RYCEY), Blink Charging (BLNK), Cameco (CCJ), Ford Motor (F) and iShares U.S. Infrastructure ETF (IFRA). Company Calendar Last Earnings8/14/2025Today6/24/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2w+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 For the last 2 weeks, GCTK's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED PRODUCTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:GCTK CIK1506983 Webwww.glucotrack.com Phone(201) 842-7715Fax972-8675-7850Employees5Year FoundedN/AProfitability EPS (Trailing Twelve Months)($18.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$19.39 million Net MarginsN/A Pretax MarginN/A Return on Equity-581.98% Return on Assets-220.10% Debt Debt-to-Equity Ratio0.08 Current Ratio0.85 Quick Ratio0.85 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.80 per share Price / Book0.13Miscellaneous Outstanding Shares6,260,000Free Float6,119,000Market Cap$2.28 million OptionableNot Optionable Beta0.72 The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:GCTK) was last updated on 6/24/2026 by MarketBeat.com Staff. From Our PartnersMy feud with Zohran MamdaniNearly 40% of Americans now hold a positive view of socialism - and former hedge fund manager Whitney Tilson s...Stansberry Research | SponsoredQuick favor to ask youBill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $...Profits Run | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredTop Banks Warn: A Strange Day is Coming to AmericaGoldman Sachs and Morgan Stanley are warning clients about a developing crisis that could suppress portfolio g...TradeSmith | SponsoredA drilling crew just broke a record nobody expectedA drilling crew in Beaver County, Utah hit 15,765 feet of solid granite in 16 days - a job the Department of E...Behind the Markets | SponsoredRead this before you touch SPCXSPCX is live on Nasdaq - but a market expert who called AMD before it climbed as high as 7,100% says buying th...Altimetry | SponsoredMillionaire trader who went 13-for-13 on Trump in 2025 now turns his attention to Elon.Hedge fund trader Larry Benedict went 13-for-13 in Q1 2025 - not a single losing trade - and finished the year...Brownstone Research | SponsoredKarp just filed Form 144On May 12, 2026, Palantir CEO Alex Karp filed to sell 585,000 shares - roughly $95.93 million. Combined with f...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GlucoTrack, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GlucoTrack With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
